BPC-157
Also known as: Body Protection Compound 157, PL 14736
By GLPeptideSciences Editorial Team · How we evaluate evidence · Reviewed by Dr. George S. Watson, MD, Cardiothoracic Surgeon · Updated 2026-06-02
A synthetic 15–amino-acid peptide derived from a protein found in gastric juice, studied predominantly in animal models for soft-tissue and gastrointestinal healing.
What it is & how it works
What it is
BPC-157 is a synthetic peptide — a 15-amino-acid sequence corresponding to a fragment of a protein isolated from gastric juice. The name, “Body Protection Compound,” comes from the research literature, not from any proven clinical property, and that distinction is the whole story of this compound. It has been studied since the 1990s, almost entirely in animal models, and it has become the single most-discussed peptide in the recovery space — which makes the gap between its reputation and its human evidence worth understanding precisely.
How it is thought to work
The proposed mechanisms come from preclinical work and are genuinely interesting. In animal studies BPC-157 is associated with angiogenesis — the formation of new blood vessels, which supports tissue repair — and with modulation of growth-factor and nitric-oxide signaling. It has shown protective effects across a striking range of rodent models: tendon and ligament injury, muscle damage, and gut irritation in particular. Researchers describe a broad “cytoprotective” effect rather than a single targeted action. The honest framing: these are mechanistic hypotheses from animal data, not established human pharmacology.
The evidence gap — stated plainly
This is where credibility lives. The animal literature is unusually consistent and repeated, and that consistency is exactly why the compound is interesting and why it refuses to go away. But consistency in rodents is not a demonstrated effect in people. There are no large, registered, controlled human trials establishing that BPC-157 works or is safe in humans — the human side is entirely anecdotal. Anyone telling you the human case is settled is overstating what exists. The interesting-but-unproven status is the accurate one.
The real-world risk is sourcing, not the molecule
Here is the practical point most discussions bury: for BPC-157 specifically, the dominant real-world risk isn’t the peptide’s intrinsic profile (which looks low-toxicity in animals) — it’s what’s actually in the vial. Gray-market product varies widely in purity, identity, and sterility, and an unsterile or contaminated injectable is a more immediate hazard than anything the peptide itself is likely to do. If someone engages with BPC-157, independent third-party testing — HPLC/MS for identity and purity, plus endotoxin and sterility checks — matters far more than any marketing claim. “Research use only” describes regulatory status, not a quality grade.
One more practical note
BPC-157 is on the World Anti-Doping Agency Prohibited List, so it’s banned for tested athletes — a relevant detail for anyone competing under drug-tested rules. Taken together, BPC-157 is the clearest case study on this whole site of a compound with a real, repeatable animal story, a genuinely unproven human one, and a risk profile dominated by the unregulated market it’s sold through.
What it's discussed & studied for
- Tendon and ligament recovery
- Gut and GI irritation
- Muscle and soft-tissue injury
- Wound healing
Discussion of a use is not a claim that it works or is approved.
Research status
Extensive rodent and in-vitro literature; no large registered human trials establishing efficacy or safety.
Evidence quality
Largely preclinical. Mechanistic findings in animals are consistent and repeated, but have not been confirmed in controlled human studies. Human reports are anecdotal.
Dosing discussion
Community discussion commonly references microgram-to-low-milligram subcutaneous protocols run in short cycles, sometimes near the site of an injury. No human dose is clinically established or validated.
Educational summary of what is discussed in the literature and community — not a dosing recommendation or medical advice.
Safety & harm reduction
Animal toxicity appears low across studies, but human safety is genuinely uncharted. In practice the dominant real-world risks are sourcing-related: purity, sterility, and contamination from gray-market product. Not approved by the FDA for human use.
Sourcing literacy
Independent third-party testing (HPLC/MS for identity and purity, plus endotoxin/sterility) matters far more than marketing claims. 'Research use only' labeling reflects regulatory status, not a quality grade.
Selected literature
- PubMed: BPC-157 research literature — Most results are animal or in-vitro studies.
- ClinicalTrials.gov: registered human studies — Check how few human trials are registered and their status.
FAQ
Is BPC-157 FDA-approved?
No. It is not approved for human use in the United States. Most available product is labeled for research use only.
Is the evidence for BPC-157 from human trials?
Overwhelmingly no. The supportive data is from rodent and in-vitro studies. Human use is anecdotal and unverified.
What's the biggest practical risk?
Sourcing. Unregulated product can vary widely in purity and sterility, which is a more immediate concern than the peptide's intrinsic profile.
Is BPC-157 banned in sport?
Yes — the World Anti-Doping Agency added BPC-157 to its Prohibited List, so it is banned for tested athletes.